hromboxane (TX) A2 and prostaglandin (PG) I2 are extremely labile susbstances, with half-lives of 30 s and 10 min, respectively. PGI2 and TXA2 have the opposite effects on platelet aggregation and vascular smooth muscle: PGI2 inhibits platelet aggregation 1 and induces relaxation of vascular smooth muscle, 2 whereas TXA2 induces platelet aggregation 3 and powerful contraction of vascular smooth muscle. 4, 5 As a spasm provocation test, intracoronary injection of acetylcholine (ACh) is clinically used in the cardiac catheterization laboratory 6, 7 because ACh is superior to ergonovine for the induction of multiple spasms. 8 It is also known that coronary artery spasms can activate the coagulation system in the coronary circulation 9 and that an increase in platelet aggregates in peripheral and coronary sinus blood occurs in patients with coronary spastic angina. 10 Moreover, elevation of TXB2 concentrations in patients with variant angina in peripheral and coronary sinus blood has been reported. 11, 12 It is possible that a transient imbalance between TXA2 and PGI2 is temporally associated with the development of coronary spasms. Intravenous administration of PGI2 and aspirin failed to prevent attacks of vasospastic angina, despite decreasing the TXB2 concentration, when they were trialled approximately 20 years ago, [13] [14] [15] but it is still not known whether intracoronary administration of a TXA2 synthase inhibitor can relieve coronary spasms locally.
We sought to clarify the effectiveness of intracoronary administration of a TXA2 synthase inhibitor, Ozagrel Na, to relieve coronary spasms induced by the intracoronary injection of ACh.
Intracoronary Administration of a Thromboxane A2
Synthase Inhibitor Relieves AcetylcholineInduced Coronary Spasm 
ACh Spasm Provocation Test
Coronary arteriography was carried out after injection of 8-10 ml of Iopamiron (Schering) with the Sones technique in the morning and afternoon (from 10.00 h to 16.00 h) under no medication for at least 24 h. A USCI bipolar electrode catheter was inserted into the right ventricular apex through the femoral vein and connected to a temporary pacemaker set at a rate of 45 beats/min. As previously reported, [16] [17] [18] [19] [20] [21] [22] provocation of coronary vasospasms was performed with intracoronary injections of ACh at incremental doses of 20, 50 and 80 g into the right coronary artery and 20, 50 and 100 g into the left coronary artery over 20 s with at least a 3-min interval between each injection. Coronary arteriography was performed when STsegment changes, chest pain or both occurred and there was a 1-min interval until spasm relief. When a coronary spasm was induced, a 20 mg intracoronary bolus of TXA2 synthase inhibitor, Ozagrel Na, was administered into the responsible vessel. Moreover, if the coronary spasm did not resolve within 3 min or if hemodynamic instability occurred, 2.5-5.0 mg of isosorbide dinitrate was injected into the responsible vessel. During the study, arterial blood pressure and an electrocardiogram (ECG) lead (II) were continuously monitored on an oscilloscope with a Nihon-Kohden polygraph. A standard 12-lead ECG was recorded every 30 s.
Spontaneous Relief vs Effect of Ozagrel Na in ACh-Induced Spasms
In 7 of the patients we compared serial coronary angiography with and without an intracoronary bolus injection of Ozagrel Na during ACh-induced spasms. Coronary spasms were provoked by ACh in 5 right coronary arteries and 2 left anterior descending arteries, and coronary arteriography was performed at 1-min intervals until TIMI 3 flow was achieved. 23 All 7 patients had the same spasm configurations and sites on a second ACh test, which was performed 15 min after the first. Spasm relief time, maximal ST segment elevation and frequency of chest pain were compared between the 2 tests.
TXB2 and 6-Keto PGF1 Concentrations in the Coronary Sinus After Intracoronary Injection of Ozagrel Na
In 4 patients with ACh-induced coronary spasm of the left anterior descending artery, a 7F coronary sinus flow catheter was positioned in the coronary sinus and its position was confirmed by injection of a contrast medium. Before the ACh spasm provocation test, during spasm relief by Ozagrel Na and 10 min later, 10 ml of blood were withdrawn from the coronary sinus and the concentrations of thromboxane B2 and 6-keto PGF1 were measured by radioimmunoassay. Only one patient (case No. 4) had taken aspirin prior to the study.
Angiographic Analysis
Coronary arteriograms were analyzed separately by 2 independent observers. Coronary vasospasms were assessed as TIMI 0 or TIMI 1 flow. 23 Catheter-induced spasms were excluded from this study. Significant organic stenosis was defined as >75% luminal narrowing. Coronary arteries were measured after intracoronary administration of isosorbide dinitrate (2.5-5.0 mg) to evaluate coronary atherosclerosis according to the American Heart Association classification system. 24 A focal spasm was defined as a discrete transient vessel narrowing (>99%) localized in one major coronary artery and a diffuse spasm was diagnosed when transient vessel narrowing less than 99%, compared with the baseline coronary angiography, was observed from the proximal to distal segments in the 3 major coronary arteries. Coronary spasm relief was defined as TIMI 3 flow.
The degree of ST-segment depression was measured 80 ms after the J point, and was considered positive if at least one of the following ischemic ECG changes was 
Statistical Analysis
All values are expressed as the mean ± SD. Differences among proportions were analyzed by the chi-square test with correction or the ANOVA test. P<0.05 was considered significant. (Table 2) Within 2 min, ACh-induced coronary spasms were relieved in 88.1% of procedures and only 4 cases (4.3%) took more than 3 min to gain relief. In those 4 cases, intracoronary administration of Ozagrel Na had little effect on the coronary spasms, and in 2 of them intracoronary isosorbide dinitrate was necessary. Major complications such as refractory spasms, ventricular tachycardia/fibrillation or myocardial infarction were not observed in this study. The effectiveness of Ozagrel Na on both coronary arteries was not different.
Results

Effectiveness of Ozagrel Na in ACh-Induced Spasms
Comparison Between Natural Spasm Relief and the Effect of Ozagrel Na
After intracoronary administration of 20 mg Ozagrel Na, the relief time of ACh-induced spasms was significantly shortened (200±59 s vs 111±23 s, p<0.01), ST elevation disappeared in 5 of the 7 patients and chest pain disappeared in 4 patients (Table 3) . Representative cases are shown in Figs 1 and 2 . The maximal ST segment elevation was markedly suppressed after intracoronary Ozagrel Na during ACh-induced spasms (Fig 1) . Moreover, coronary spasms were not relieved naturally within 2 min, but intracoronary injection of 20 mg Ozagrel Na achieved TIMI 3 flow with 1 min. In addition, 2 min after Ozagrel Na, the right coronary artery was dilated (Fig 2) .
TXB2 and 6-Keto PGF1 Concentrations in the Coronary Sinus During ACh-Induced Spasms and After Ozagrel Na
All 4 patients had coronary spasm of the left anterior descending artery and intracoronary administration of Ozagrel Na was performed in all cases (Table 4) . TXB2 concentration decreased after spasm relief (463±562 pg/ml vs 96±45 pg/ml, p<0.05) and returned to the baseline level after 10 min, administration of Ozagrel Na (628±978 pg/ml). The TXA2 synthase inhibitor prevented a significant increase in the coronary sinus concentration of TXB2 after ACh-induced spasm, but had little effect on the concentration of 6-keto-PGF1 .
Discussion
In previous reports, TXA2 synthase inhibitors have shown potential for reducing infarct size and in the treatment of angina pectoris, 25, 26 but the administration of the TXA2 synthase inhibitor was systemic in the majority of the previous reports. Selective, intracoronary injection of a TXA2 synthase inhibitor has not been reported until now when we have shown that intracoronary TXA2 synthase inhibitor relieved coronary artery spasms induced by intracoronary injection of ACh. Therefore, we recommend that a TXA2 synthase inhibitor, as well as isosorbide dinitrate, should be administered for local relief of ACh-induced spasms.
Possible Mechanism of Selective Spasm Relief
Large doses of aspirin aggravate variant angina by blocking PGI2 synthesis, although smaller doses has been reported as effective in reducing myocardial infarction. 27 Shimokawa et al reported that in miniature pigs intravenous PGI2 infusion failed to prevent histamine-induced coronary artery spasms, whereas intracoronary administration of thiothromboxane A2 markedly constricted all epicardial coronary arteries, but failed to provoke coronary artery spasm. 28 Chierchia et al also reported that TXA2 blockade failed to prevent attacks of vasospastic angina, and that PGI2 infusion also failed to block ergonovine-induced coronary vasospasms. 29, 30 In contrast, Szczeklik et al reported that infusion of PGI2 caused angina in 5 of 7 patients with angina at rest, 31 and Ohmori et al also reported that in 7 of 8 patients with ergonovine-induced spasms, intravenous infusion of TXA2 synthase inhibitor attenuated the increased spasticity with reduction of coronary sinus concentrations of TXB2. 32 Thus from those reports, it remains controversial whether intracoronary administration of a TXA2 synthase inhibitor can relieve ACh-induced coronary artery spasms.
Intracoronary injection of ACh induces spasms via the muscarinic receptors. 33 Endothelium-derived relaxing factors, such as NO, PGI2, endothelium-derived hyperpolarizing factor and endothelium-derived constricting factors (TXA2 and PGH2), are released from the endothelium after intracoronary injection of ACh. 34, 35 The ACh-induced spasm stimulates the endothelium and platelet aggregation, and accelerates the synthesis of TXA2 in the endothelium of the coronary artery. The increased TXA2 and PGH2 concentrations lead to constriction of the coronary artery and in this situation, intracoronary administration of plenty of a TXA2 synthase inhibitor may inhibit TXA2 synthesis in the coronary circulation, thus playing a major role in coronary spasm relief.
The spontaneous release of TXB2 from the cerebral artery is approximately 10-fold higher than that of the coronary, mesenteric and saphenous arteries. 36 It has been reported that a TXA2 synthase inhibitor was effective in the cerebral circulation, and if the local concentration of TXB2 is high in ACh-induced spasms, a large amount of TXA2 synthase inhibitor could block TXB2 synthesis in the coronary circulation and give spasm relief. However, because not only PG but other factors as well are involved in causing the coronary spasm, the effectiveness of intracoronary injection of a TXA2 synthase inhibitior to relieve ACh-induced spasms has critical limitations in the clinical situation.
Clinical Implications
Peripheral administration of a TXA2 synthase inhibitor and PGI2 did not relieve coronary spasms clinically. However, the present study proved there is a clinical possibility for selective and local administration of a TXA2 synthase inhibitor for relief of ACh-induced spasms. Intracoronary administration of a TXA2 synthase inhibitor may reduce the amount of isosorbide dinitrate needed, and may lead to the diagnosis of spasms strictly according to whether or not there are other coronary artery spasms. If a TXA2 synthase inhibitor relieves ACh-induced spasms without the need to wait for spontaneous relief, we can perform ACh spasm provocation tests more safely. Because the pathogenesis of coronary artery spasms involves multiple factors in the clinical situation, intracoronary administration of a TXA2 synthase inhibitor may be useful for spasms that are refractory to isosorbide dinitrate.
Study Limitations
We did not have a placebo control for the effects of the TXA2 synthase inhibitor, so possible preconditioning effects cannot be excluded. However, spontaneous spasm relief was often observed in the ACh tests within a few minutes. We performed ACh tests with and without administration of a TXA2 synthase inhibitor in only 7 patients (7.6%), not in all 92 patients. All 7 patients had spasm relief after 20 mg of Ozagrel Na, but further study is necessary to investigate the TXA2 effect in relieving coronary spasms in many patients, including those with ergonovine-induced spasms.
